Search
Teprotumumab
go.drugbank.com/drugs/DB06343ApprovedInvestigationalTeprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. … multiple invasive surgeries - teprotumumab is the first drug ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease.
Categories: Insulin-like Growth Factor-1 Receptor InhibitorSynonyms: Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human monoclonal heavy chain), disulfide with human monoclonal light chain, dimerKB3305
go.drugbank.com/drugs/DB06349ExperimentalKB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.
Synonyms: (4R)-4-((3S,5R,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-DIHYDROXY-3-(2-(4-((8S,11R,13S,14S,17S)-17-HYDROXY-13-METHYL-3-OXO-17-PROP-1-YNYL-1,2,6,7,8,11,12,14,15,16-DECAHYDROCYCLOPENTA(A)PHENANTHREN-11-YL)-N-METHYL-ANILINO, 3.BETA.,5.BETA.,7.ALPHA.,12.ALPHA.)-7,12-DIHYDROXY-3-(2-((4-((11.BETA.,17.BETA.)-17-HYDROXY-3-OXO-17-(1-PROPYN-1-YL)ESTRA-4,9-DIEN-11-YL)PHENYL)METHYLAMINO)ETHOXY)CHOLAN-24-OIC ACIDTRC093
go.drugbank.com/drugs/DB06356InvestigationalTRC093 is a recombinant humanized IgG1k monoclonal antibody.
XR5944
go.drugbank.com/drugs/DB06364ExperimentalXR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.
Categories: Heterocyclic Compounds, 3-RingSapacitabine
go.drugbank.com/drugs/DB06365InvestigationalSynonyms: 1-(2-C-cyano-2-deoxy- ß-D-arabino-pentafuranosyl)-N4-palmitoylcytosineCategories: Heterocyclic Compounds, 1-RingAlamifovir
go.drugbank.com/drugs/DB06368ExperimentalAlamifovir is an antiviral agent specific for HBV.
Categories: Heterocyclic Compounds, 2-RingCHGN111
go.drugbank.com/drugs/DB06376ExperimentalCHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase. … Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative
NRP290
go.drugbank.com/drugs/DB06383ExperimentalNRP290 is a hydrocodone derivative under investigation for the treatment of pain (moderate to moderately severe).